Medical Science is known to have prolonged the standard human lifespan. Since the public health programmes for the treatment of infectious diseases like cancer, the population of the 60-year-old has increased since 1980.
According to research, by 2050, this number will be 2 billion, leading to an increase in the number of old people with chronic degenerative health conditions like age and cancer. According to Research Gate, that is why Mikhail Blagosklonny is instrumental in the field of cancer and age research.
Impact Journals reported exclusively that the world jeers Mikhail Blagosklonny for his original theory on the possible action of TOR signaling, a protein that can be used to reduce aging and treat cancer. Mr. Mikhail is a New York-based scientist who studies aging and cancer at the Institute of Rosewell Park. He formulated the TOR signaling through rapamycin, a prominent cancer drug that can be used to curb age and prolong human lives.
Mikhail’s prominence roots from his passionate advocacy in the rapamycin longevity research. Rapamycin is a macrolide element used to coat coronary stents while preventing the possible rejection of an organ transplant in the bodies. It is also used to treat lymphangioleiomyomatosis, a lung disease.
Education and Career
Mikhail Blagosklonny earned his first degree and PhD in internal and experimental medicine from the First Pavlov State Medical University of St. Peterburg. In 2002, he was appointed the medicine associate professor at New York Medical College before being named the senior scientist of Ordway Research Institute in New York.
Following his passion and dedication to cancer research, treatment and therapies, Blagosklonny was appointed the professor of oncology at Rosewell Park Cancer Institute. Blagosklonny’s research capitalizes on cancer treatments that offer protection to the damaging elements of healthy cells and anti-ageing elements.
Mikhail Blagosklonny has extensive editorial activities. He is the author of hyperfunction hypothesis of ageing and anti-cancer approaches like cyclotherapy and chemotherapeutic engineering. He is the publisher of over 250 articles book chapters and cancer research reviews.
Mikhail Blagosklonny serves as the Founding Editor and Editor –in-Chief of the book Cell Cycle beside being the Co-editor of Aging, Oncoscience and Oncotarget. His vast experience led to his appointment as the Associate Editor for Cancer Biology and Therapy, Cell Death and Differentiation, The American Journal of Pathology and International Journal of Cancer.